deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01504126

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Sponsor: M.D. Anderson Cancer Center

Conditions Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Stage II Fallopian Tube Cancer AJCC v6 and v7 Stage II Ovarian Cancer AJCC v6 and v7 Stage IIA Fallopian Tube Cancer AJCC v6 and v7 Stage IIA Ovarian Cancer AJCC V6 and v7 Stage IIB Fallopian Tube Cancer AJCC v6 and v7 Stage IIB Ovarian Cancer AJCC v6 and v7 Stage IIC Fallopian Tube Cancer AJCC v6 and v7 Stage IIC Ovarian Cancer AJCC v6 and v7 Stage III Fallopian Tube Cancer AJCC v7 Stage III Ovarian Cancer AJCC v6 and v7 Stage III Primary Peritoneal Cancer AJCC v7 Stage IIIA Fallopian Tube Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIB Fallopian Tube Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIC Fallopian Tube Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7
Interventions Chemotherapy Propranolol Hydrochloride Quality-of-Life Assessment Therapeutic Conventional Surgery
Updated 10 times since 2017 Last updated: Aug 27, 2019 Started: Mar 9, 2012 Primary completion: Aug 15, 2019 Completion: Aug 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Fallopian Tube Clear Cell Adenocarcinoma and Fallopian Tube Endometrioid Adenocarcinoma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 10 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshotActive Not Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotActive Not Recruiting~Aug 2018 – ~Jun 2019 · 10 months · monthly snapshotActive Not Recruiting~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshotActive Not Recruiting~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

  4. Sep 2019 — Jan 2021 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed · Phase: NA → EARLY_PHASE1

  5. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting NA

▶ Show 5 earlier versions

  1. Aug 2018 — Jun 2019 [monthly]

    Active Not Recruiting NA

  2. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting NA

  3. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting NA

  4. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting NA

  5. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting NA

    First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
  • Sprint for Life
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations